Literature DB >> 9727710

Decreased gene expression of endothelial nitric oxide synthase in newborns with persistent pulmonary hypertension.

M E Villanueva1, F M Zaher, D M Svinarich, G G Konduri.   

Abstract

Previous studies in adults have shown that chronic pulmonary hypertension is associated with decreased endothelial nitric oxide synthase (eNOS) expression in pulmonary arteries. However, the role of decreased eNOS expression in persistent pulmonary hypertension of the newborn (PPHN) is unknown. We investigated the hypothesis that umbilical vein endothelial cells cultured from infants with PPHN will have decreased eNOS expression. Umbilical cords were collected from meconium-stained infants at birth, and endothelial cells were isolated if the infants developed PPHN. Endothelial cells were grown in primary culture, and total RNA was isolated. cDNA was reverse transcribed from mRNA and amplified by PCR. An expected product of approximately 550 bp was found in all control infants but only in two of the six infants with PPHN. Identity of the PCR product was confirmed by Southern hybridization to a separate internal eNOS-specific probe. Amplification of beta-actin cDNA, an internal control, was detected in all controls and in all infants with PPHN, including the four infants without the eNOS band. There was no difference in the course and outcome of patients with presence or absence of the eNOS band. However, there was an acidotic arterial blood pH (7.19-7.29) and intrapartum fetal heart rate decelerations in all four infants without eNOS expression. In conclusion, eNOS mRNA was detected in all normal term infants but was notably absent in the majority of infants with PPHN in this pilot study. The development of PPHN is multifactorial, and a decrease in eNOS gene expression may occur in some infants. Whether the decreased eNOS transcript is a cause of PPHN or a result of intrapartum stress remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9727710     DOI: 10.1203/00006450-199809000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  24 in total

Review 1.  Nitric oxide and beyond: new insights and therapies for pulmonary hypertension.

Authors:  R H Steinhorn
Journal:  J Perinatol       Date:  2008-12       Impact factor: 2.521

Review 2.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

3.  Decreases in manganese superoxide dismutase expression and activity contribute to oxidative stress in persistent pulmonary hypertension of the newborn.

Authors:  Adeleye J Afolayan; Annie Eis; Ru-Jeng Teng; Ivane Bakhutashvili; Sushma Kaul; Jonathan M Davis; Girija G Konduri
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-09-07       Impact factor: 5.464

Review 4.  Role of reactive oxygen species in neonatal pulmonary vascular disease.

Authors:  Stephen Wedgwood; Robin H Steinhorn
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 5.  Neonatal pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

Review 6.  Factors relating caesarean section to persistent pulmonary hypertension of the newborn.

Authors:  Niralee Babooa; Wen-Jing Shi; Chao Chen
Journal:  World J Pediatr       Date:  2017-10-20       Impact factor: 2.764

7.  Update on PPHN: mechanisms and treatment.

Authors:  Jayasree Nair; Satyan Lakshminrusimha
Journal:  Semin Perinatol       Date:  2014-03       Impact factor: 3.300

8.  Intrauterine pulmonary hypertension impairs angiogenesis in vitro: role of vascular endothelial growth factor nitric oxide signaling.

Authors:  Jason Gien; Gregory J Seedorf; Vivek Balasubramaniam; Neil Markham; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2007-09-06       Impact factor: 21.405

Review 9.  Vascular repair and regeneration as a therapeutic target for pulmonary arterial hypertension.

Authors:  Laszlo Farkas; Martin Kolb
Journal:  Respiration       Date:  2013-03-22       Impact factor: 3.580

10.  Chronic intrauterine pulmonary hypertension increases endothelial cell Rho kinase activity and impairs angiogenesis in vitro.

Authors:  Jason Gien; Gregory J Seedorf; Vivek Balasubramaniam; Nancy Tseng; Neil Markham; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-11       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.